Skip to main content
Annals of Intensive Care

Table 1 Basic characteristics of cohorts

From: Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COVID-19 disease severity and indicator of the need for mechanical ventilation, ARDS and mortality

 

COVID-19 Pneumonia (n = 164)

Non-COVID-19 Pneumonia (n = 23)

COVID-19 Convalescent

Healthy Controls

Disease severity

Disease severity

mild (n = 75)

moderate (n = 57)

severe (n = 32)

moderate (n = 14)

severe (n = 9)

n = 101

n = 15

Gender

 Male

32 (42.7%)

31 (54.4%)

26 (81.3%)

10 (71.4%)

6 (66.7%)

48 (47.5%)

6 (40%)

 Female

43 (57.3%)

26 (45.6%)

6 (18.8%)

4 (28.6%)

3 (33.3%)

53 (52.5%)

9 (60%)

Age

57 (53–60)

57 (55–64)

69 (64–77)

53 (45–69)

68 (63–81)

60 (58–62)

36 (34–52)

BMI

25.8 (24.9–26.6)

26.9 (25.3–29.4)

26.0 (24.8–26.9)

24.9 (23.1–31.6)

28.4 (26.4–31.2)

26.4 (25.7–27.4)

22.5 (20.9–25.3)

A.Hypertension

20 (26.7%)

24 (42.1%)

23 (71.9%)

9 (64.3%)

7 (77.8%)

38 (37.6%)

0

CAD

3 (4.0%)

1 (1.8%)

10 (31.3%)

3 (50%)

 

4 (4%)

0

Diabetes mellitus

8 (10.7%)

7 (12.3%)

8 (25.0%)

2 (14.3%)

2 (22.2%)

11 (10.9%)

0

Hyperlipidemia

14 (18.7%)

11 (19.3%)

12 (37.5%)

4 (28.6%)

4 (44.4%)

16 (15.8%)

0

Renal insufficiency

1 (1.3%)

5 (8.8%)

8 (25.0%)

6 (42.9%)

5 (55.6%)

4 (4%)

0

COPD

1 (1.3%)

4 (7.0%)

4 (12.5%)

0 (0%)

1 (11.1%)

3 (3.0%)

0

Inflammatory diseases

11 (14.7%)

9 (15.8%)

2 (6.3%)

8 (57.1%)

1 (11.1%)

16 (15.8%)

0

Malignancy

10 (13.3%)

7 (12.3%)

5 (15.6%)

0 (0%)

1 (11.1%)

13 (12.9%)

0

ACE-I

6 (8.0%)

8 (14.0%)

12 (37.5%)

4 (28.6%)

3 (33.3%)

11 (10.9%)

0

ARB

7 (9.3%)

9 (15.8%)

6 (18.8%)

2 (14.3%)

3 (33.3%)

15 (14.9%)

0

Cortisone

2 (2.7%)

5 (8.8%)

6 (18.8%)

1 (7.1%)

2 (22.2%)

5 (5.0%)

0

Statins

10 (3.3%)

11 (19.3%)

11 (34.4%)

4 (28.6%)

3 (33.3%)

16 (15.8%)

0

ASS/Clopidogrel

7 (9.3%)

6 (10.5%)

9 (28.1%)

2 (14.3%)

3 (33.3%)

8 (7.9%)

0

PaO2:FiO2

 

363 (329–410)

138 (106–179)

349 (307–400)

137 (118–232)

  

30-day mortality

0 (0%)

0 (0%)

11 (34.4%)

0 (0%)

3 (33.3%)

  

Dialysis

0 (0%)

0 (0%)

8 (25.0%)

2 (14.3%)

3 (33.3%)

  

Catecholamine

0 (0%)

0 (0%)

13 (40.6%)

0 (0%)

5 (55.6%)

  

SOFA

0

1 (1–2)

5 (4–7)

2 (1–6)

6 (4–13)

  

Maximum SOFA

0

1 (1–2)

10 (5–13)

2 (1–6)

11 (6–14)

  

qSOFA

 0

75 (100%)

46 (80.7%)

9 (28.1%)

11 (78.6%)

1 (11.1%)

  

 1

0 (0%)

9 (15.8%)

17(53.1%)

3(21.4%)

4 (44.4%)

  

 2

0 (0%)

2 (3.5%)

6 (18.8%)

0 (0%)

2 (22.2%)

  

 3

0 (0%)

0 (0%)

0 (0%)

0 (0%)

2 (22.2%)

  
  1. Table shows the demographic characteristics, medical history and clinical data of cohorts with COVID-19 pneumonia, non-COVID-19 pneumonia, 20 weeks convalescent and healthy controls. Nominal and ordinal variables are reported as count (percentage in cohort), continuous variables are reported as median (IQR). BMI body mass index, A. Hypertension arterial hypertension, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, SOFA sequential organ failure assessment score, qSOFA quick sequential organ failure assessment score
Back to article page